Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 134 • 2016 ACR/ARHP Annual Meeting
Synovitis Assessed By the German 7-Joint Ultrasound Score (US7S) Is Associated with the Reversible Activity-Related Component of Physical Disability in Patients with Rheumatoid Arthritis
Jakub Zavada¹, Petra Hanova¹, Jana Hurnakova¹, Lenka Szczukova², Michal Uher², Šárka Forejtová¹, Martin Klein¹, Heřman F Mann¹, Marta Olejarova¹, Olga Sleglova¹, Olga Ruzickova¹ and Karel Pavelka¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic
Background/Purpose: Restoring normal functioning is a major therapeutic aim. Differences in the sources of functional limitations should be considered in the interpretation of functional measures.…
Abstract Number: 1054 • 2016 ACR/ARHP Annual Meeting
Self-Reported Psychological Impact and Coping Strategies of Men with RA
Caroline Flurey¹, Sarah Hewlett², Karen Rodham³, Alan White⁴, Robert Noddings⁵ and John Kirwan⁶, ¹Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ³Psychology, Sport and Exercise, Staffordshire University, Stoke on Trent, United Kingdom, ⁴Centre for Men's Health, Leeds Beckett University, Leeds, United Kingdom, ⁵Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁶University of Bristol, Bristol, United Kingdom
Background/Purpose: Current RA research reflects the preponderance of women with the condition (30% male). Research in other conditions suggests men need their own health strategy.…
Abstract Number: 1737 • 2016 ACR/ARHP Annual Meeting
Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital
Catalina Gómez-Arango¹, M. Luz García-Vivar¹, Montserrat Alonso-Diez², M. Milagros Alvarez-Lavin², Eva Galindez-Agirregoikoa³, Olaia Fernández-Berrizbeitia³, Esther Ruíz-Lucea¹, Juan María Blanco-Madrigal¹, Jose Francisco Garcia-Llorente¹, Lidia Estopiñán-Fortea³, Ignacio Torre-Salaberri⁴, Edurne Guerrero-Basterretxea³, Itziar Calvo-Zorrilla³, Amaia Bilbao-González⁵ and Natalia Rivera-García⁵, ¹Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ²Pharmacy Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁴Rheumaytology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁵Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Rheumatic inflammatory arthropaties such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthrities (SpA) are chronic diseases that require adequate therapies, sometimes biological drugs,…
Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Arthur F. Kavanaugh¹, Jamie Geier², Clifton Bingham III³, Connie Chen², George W. Reed^4,5, Katherine C. Saunders⁴, Yan Chen⁶, Andrew Koenig⁶, Laura Cappelli⁷, Jeffrey D. Greenberg^4,8 and Joel M. Kremer⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Pfizer, Inc., New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Pfizer, Inc., Collegeville, PA, ⁷Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸NYU School of Medicine, New York, NY, ⁹Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Joel M. Kremer¹, Edward C. Keystone², Paul Emery³, Heidi S. Camp⁴, Alan Friedman⁴, Li Wang⁴, Ahmed A. Othman⁴, Nasser Khan⁴ and Steven Jungerwirth⁴, ¹Albany Medical College, Albany, NY, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…
Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Lindsay Claxton¹, Matthew Taylor¹, Michelle Jenks¹, Gene Wallenstein², Alan Mendelsohn³, Jeffrey Bourret³, Amitabh Singh³ and Robert Gerber², ¹York Health Economics Consortium, University of York, York, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…
Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Venkat Reddy¹, Christian Klein², David A. Isenberg³, Geraldine Cambridge⁴, Martin Glennie⁵, Mark Cragg⁶ and Maria J. Leandro¹, ¹Rheumatology, University College London, London, United Kingdom, ²Roche Pharmaceutical Research & Early Development Oncology Discovery & Translational Area, Roche Glycart AG, Schlieren, Switzerland, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Rheumatology, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, ⁵Antibody and Vaccine group, Southampton University, Southampton, United Kingdom, ⁶Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…
Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Irina Lazariciu⁶, Chudy Nduaka⁷, Carol A. Connell⁴, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
Abstract Number: 2720 • 2015 ACR/ARHP Annual Meeting
Crucial Role of Nuclear Factor of Activated T Cell 5 (NFAT5), an Osmo-Protective Factor, in Migration and Invasion of Rheumatoid Synoviocytes
Saseong Lee¹, Seung-Ah Yoo¹, Ki-Jo Kim², Chong-Hyeon Yoon³, Wan-Uk Kim⁴ and Bong Ki Hong¹, ¹Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea, ²St. Mary's Hospital, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) play an important role in the progression of rheumatoid arthritis (RA). Particularly, FLS of RA patients (RA-FLS) exhibit pro-migratory and invasive…
Abstract Number: 128 • 2015 ACR/ARHP Annual Meeting
Economic Burden and Treatment Patterns of Cycling Between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) Among Patients with Rheumatoid Arthritis (RA)
Nanxin Li¹, Keith Betts¹, Jenny Griffith², Ljubica Ristovska¹, Kevin Douglas² and Arijit Ganguli², ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: RA patients with inadequate treatment response often cycle non-biologic DMARDs before initiating a biologic DMARD. Early and aggressive treatment is a key feature of…
Abstract Number: 1169 • 2015 ACR/ARHP Annual Meeting
Crossregulatory Mechanisms Between Synovial Fibroblasts and Macrophages Relevant in RA Pathogenesis
Jennifer Ding¹, Lionel B. Ivashkiv² and Laura T. Donlin¹, ¹Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Macrophages and synovial fibroblasts function as key drivers of inflammation in rheumatoid arthritis (RA). We have developed a co-culture system that aims to define…
Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Benjamin Chastek¹, Jeffrey R. Curtis², Laura K. Becker³, George J. Joseph⁴ and Chieh-I Chen⁵, ¹Optum Insight, Eden Prairie, MN, ²University of Alabama at Birmingham, Birmingham, AL, ³Optum, Eden Prairie, MN, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…
Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Cristiano Zerbini¹, Sebastiao Radominski², Mario H. Cardiel³, Oswaldo Castañeda⁴, Ferope Romero⁵, Gustavo Citera⁶, Oscar Neira⁷, Dario Ponce de Leon⁸, Elaine Hoffman⁹ and Ricardo Rojo¹⁰, ¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ²Universidade Federal do Paraná, Curitiba, Brazil, ³Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁴Clínica Angloamericana, Lima, Peru, ⁵Hospital Arzobispo Loayza, Lima, Peru, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Hospital del Salvador, Clínica Alemana, Santiago, Chile, ⁸Pfizer Inc, Lima, PA, Peru, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…
Abstract Number: 152 • 2015 ACR/ARHP Annual Meeting
Anti-CCP Positive Patients without Clinical Synovitis Progress If Ultrasound Positive
Jackie L. Nam¹, Elizabeth M.A. Hensor¹, Laura Hunt¹, Philip G. Conaghan², Richard J. Wakefield¹ and Paul Emery³, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: To determine whether ultrasound can identify which anti-cyclic citrullinated peptide (anti-CCP) antibody positive patients with musculoskeletal (MSK) symptoms and without clinical synovitis progress to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.